BR112017006287A2 - forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesma - Google Patents
forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesmaInfo
- Publication number
- BR112017006287A2 BR112017006287A2 BR112017006287A BR112017006287A BR112017006287A2 BR 112017006287 A2 BR112017006287 A2 BR 112017006287A2 BR 112017006287 A BR112017006287 A BR 112017006287A BR 112017006287 A BR112017006287 A BR 112017006287A BR 112017006287 A2 BR112017006287 A2 BR 112017006287A2
- Authority
- BR
- Brazil
- Prior art keywords
- phenyl
- methylethyl
- cyclopentyl
- dimethylamino
- bis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C07C273/1818—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from -N=C=O and XNR'R"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055964P | 2014-09-26 | 2014-09-26 | |
| US201462086153P | 2014-12-01 | 2014-12-01 | |
| PCT/US2015/052338 WO2016049518A1 (en) | 2014-09-26 | 2015-09-25 | Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017006287A2 true BR112017006287A2 (pt) | 2017-12-12 |
Family
ID=54291659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017006287A BR112017006287A2 (pt) | 2014-09-26 | 2015-09-25 | forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesma |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9546135B2 (enExample) |
| EP (1) | EP3197435A1 (enExample) |
| JP (1) | JP2017530132A (enExample) |
| CN (1) | CN107205941A (enExample) |
| AU (2) | AU2015320358B2 (enExample) |
| BR (1) | BR112017006287A2 (enExample) |
| CA (1) | CA2962597A1 (enExample) |
| MX (1) | MX2017003916A (enExample) |
| WO (1) | WO2016049518A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| US20160287565A1 (en) * | 2015-04-06 | 2016-10-06 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| CN112441941B (zh) * | 2020-12-03 | 2022-08-02 | 浙江荣耀生物科技股份有限公司 | 一种1-(4-氨基苯基)环戊基甲腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015644A (en) * | 1987-06-02 | 1991-05-14 | Warner-Lambert Company | Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds |
| JP2005068066A (ja) | 2003-08-25 | 2005-03-17 | Air Water Chemical Inc | 2,6−ジイソプロピルアニリンの精製方法 |
| AU2011232551B2 (en) * | 2010-03-23 | 2014-11-13 | Siga Technologies, Inc | Polymorphic forms ST-246 and methods of preparation |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| JP6234987B2 (ja) | 2012-03-22 | 2017-11-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 異常な副腎皮質細胞障害を処置するための化合物および方法 |
-
2015
- 2015-09-25 US US14/866,212 patent/US9546135B2/en active Active
- 2015-09-25 AU AU2015320358A patent/AU2015320358B2/en not_active Expired - Fee Related
- 2015-09-25 CN CN201580063601.XA patent/CN107205941A/zh active Pending
- 2015-09-25 WO PCT/US2015/052338 patent/WO2016049518A1/en not_active Ceased
- 2015-09-25 EP EP15778492.7A patent/EP3197435A1/en not_active Withdrawn
- 2015-09-25 CA CA2962597A patent/CA2962597A1/en not_active Abandoned
- 2015-09-25 BR BR112017006287A patent/BR112017006287A2/pt not_active Application Discontinuation
- 2015-09-25 MX MX2017003916A patent/MX2017003916A/es unknown
- 2015-09-25 JP JP2017516764A patent/JP2017530132A/ja active Pending
-
2016
- 2016-12-06 US US15/370,980 patent/US10059660B2/en active Active
-
2019
- 2019-09-20 US US16/578,047 patent/US20200255372A1/en not_active Abandoned
-
2020
- 2020-04-27 AU AU2020202784A patent/AU2020202784A1/en not_active Abandoned
-
2021
- 2021-06-25 US US17/359,249 patent/US12151998B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2962597A1 (en) | 2016-03-31 |
| AU2020202784A1 (en) | 2020-05-14 |
| JP2017530132A (ja) | 2017-10-12 |
| US20200255372A1 (en) | 2020-08-13 |
| US20170305843A1 (en) | 2017-10-26 |
| US9546135B2 (en) | 2017-01-17 |
| US20220162160A1 (en) | 2022-05-26 |
| WO2016049518A1 (en) | 2016-03-31 |
| EP3197435A1 (en) | 2017-08-02 |
| AU2015320358A1 (en) | 2017-05-11 |
| CN107205941A (zh) | 2017-09-26 |
| AU2015320358B2 (en) | 2020-05-14 |
| MX2017003916A (es) | 2017-06-30 |
| US20160090354A1 (en) | 2016-03-31 |
| US12151998B2 (en) | 2024-11-26 |
| US10059660B2 (en) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| JOP20190174A1 (ar) | مثبطات jak1 انتقائية | |
| MX2018013983A (es) | Inhibidores g12c de kras. | |
| BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| BR112015023434A8 (pt) | compostos inibidores de histona deacetilase, seu uso e composição farmacêutica que os compreende | |
| BR112018073521A2 (pt) | polimorfos den-[(3-flúor-4-metoxipi¬ridin-2-il)metil]-3-(metoximetil)-1-({4-[(2-oxopiridin-1-il) me-til]fenil}metil)pira¬zol-4-carboxamida como inibidores de calicreína | |
| CL2010001415A1 (es) | Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo | |
| MX2019000536A (es) | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. | |
| MX2014011188A (es) | Compuestos y metodos para el tratamiento de trastornos celulares adrenocorticales aberrantes. | |
| EA201591397A1 (ru) | Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса | |
| BR112015023399A8 (pt) | inibidores de hdac, seu uso e composição farmacêutica | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| MX2016002998A (es) | Derivados novedosos de ftalazinona y su procedimiento de fabricacion. | |
| EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 | |
| CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
| MX2016007313A (es) | Uso de derivados de bencimidazol-prolina. | |
| WO2014153495A3 (en) | Novel stat3 inhibitors | |
| BR112022012205A2 (pt) | Compostos ativos para receptores nucleares | |
| CL2015000056A1 (es) | Compuestos derivados de carbamato/urea, inhibidores del receptor de histamina h3; procedimiento de preparación; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de narcolepsia. | |
| BR112018009745A8 (pt) | compostos heterocíclicos para o tratamento de doença | |
| BR112017006287A2 (pt) | forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |